Reducing levels of nicotinic alkaloids in plants
US-9834780-B2 · Dec 5, 2017 · US
US10085478B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10085478-B2 |
| Application number | US-201715828868-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 1, 2017 |
| Priority date | Feb 28, 2005 |
| Publication date | Oct 2, 2018 |
| Grant date | Oct 2, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Two genes, A622 and NBB1, can be influenced to achieve a decrease of nicotinic alkaloid levels in plants. In particular, suppression of one or both of A622 and NBB1 may be used to decrease nicotine in tobacco plants.
Opening claim text (preview).
What is claimed is: 1. A tobacco plant produced by a method comprising: (a) mutagenizing a plurality of tobacco plant cells to comprise one or more mutations in the nucleotide sequence set forth in SEQ ID NO: 3, thereby producing a plurality of mutagenized cells comprising the one or more mutations in the nucleotide sequence set forth in SEQ ID NO: 3; (b) screening plants generated from the mutagenized cells comprising the one or more mutations in the nucleotide sequence set forth in SEQ ID NO: 3 for reduced expression of NBB1; and (c) selecting one or more of the progeny comprising the one or more mutations in the nucleotide sequence set forth in SEQ ID NO: 3, wherein the progeny has reduced NBB1 expression and reduced nicotine content as compared to a control tobacco plant, thereby resulting in a tobacco plant having reduced NBB1 expression and reduced nicotine content as compared to a control tobacco plant. 2. A tobacco product produced from the tobacco plant of claim 1 , wherein: (a) the tobacco product is selected from the group consisting of smoking cessation products, cigarettes, cigarette tobacco, cigars, cigar tobacco, snus, pipe tobacco, and chewing tobacco, and (b) the tobacco product comprises the mutagenized cells of claim 1 . 3. A product produced from the tobacco plant of claim 1 , wherein: (a) the product is selected from the group consisting of a food product, food ingredient, feed product, feed ingredient, nutritional supplement, and biofuel, and (b) the product comprises the mutagenized cells of claim 1 .
Plant cells or tissues {(culture media C12N5/0025)} · CPC title
Cigars; Cigarettes · CPC title
Polymorphic or mutational markers · CPC title
Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS] · CPC title
involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.